TickerTalks
Browse all tickers →
TickerTalks›$MYO
MYMYO

Myomo, Inc.

$MYO·$62M·Medical - Devices·Healthcare
$1.58+1.3%YTD+66.3%1Y+64.7%
Price updated 10m ago·X counts updated 2d ago
MYMYO
$MYOMyomo, Inc.
$1.58+1.28%5 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $MYO on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

5X posts · last 7 days
Sep 11Sep 27

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $MYO — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Too early to tellWinding up for a moveAI verdict · as of 2026-09-28

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Myomo is up 72% YTD at 78% of the 52-week range — MyoPro upper-limb-brace commercial franchise with Q2 EPS beat +29% but small officer distribution.

Myomo Inc. is a wearable-robotics franchise (MyoPro myoelectric orthosis for stroke/SCI/TBI/brachial-plexus-injury patients) — a small-cap medical-device business through consistent EPS beats but still pre-profitability. The stock is up 77% over 12 months.

  • Q2 was a real beat: EPS -$0.07 vs -$0.098 estimate (+29%), revenue $11.7M (Q2 estimate $10.4M) at 68% gross margin — legitimate operational execution, and prior four quarters have run 11-29% surprise beats.
  • Revenue growth is real: Q1 $10.1M, Q2 $11.7M sequentially — consistent scaling in the neuromuscular-device commercial channel through Veterans Health Administration and O&P providers.
  • Insider selling is small-scale: Kovelman $20K on Sept 11, Morris $21K on Sept 2 — routine officer distribution at the current-price zone (~$1.27-$1.41), not a directional signal against the momentum.

Q3 earnings on Nov 9 is the confirmation — a beat plus firm VA-and-O&P attribution extends the story; a soft revenue trajectory or a payer-reimbursement signal and the +72% YTD tape cools.

What to watch: Q3 earnings on Nov 9 — a beat plus firm VA-and-O&P attribution extends the story; a soft revenue trajectory or a payer-reimbursement signal and the +72% YTD tape cools.

On the calendar: 2026-11-09 — Q3 earnings

no sentimentmyopro va channelconsistent eps beats

Read the AI verdict on $MYO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Medical robotics company making myoelectric arm braces (MyoPro) that restore limb function for stroke and neurological impairment patients.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $MYO.

Medical - Devices · Healthcare

Aging population demographics and AI-assisted device adoption (smart implants, continuous glucose monitors, digital health integration) are the long-cycle structural drivers. Reimbursement timing for new modalities (CMS coverage decisions) and procedure volume recovery from COVID-era deferred care shape the 2026 revenue trajectory.

What this means for $MYO

Partial — Medical robotics company making myoelectric arm braces (MyoPro) that restore limb function for stroke and neurological impairment patients.

Industry benchmark

17-name peer basket
+15.1%YTD
+26.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-3.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-45.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-27.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-17.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.2Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-142%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
68.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
3.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.07$-0.10+28.6%
Q1 2026May 7, 2026$-0.09$-0.12+25.0%
Q4 2025Mar 9, 2026$-0.08$-0.09+11.1%
Q3 2025Nov 10, 2025$-0.09$-0.11+18.2%
Next earningsMon, Nov 9·consensus EPS $-0.08

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$45.6M$44.6M – $46.6M-$0.31-$0.33 – -$0.304
FY27$51.2M$47.4M – $55.0M-$0.24-$0.27 – -$0.214
FY28$64.1M$61.2M – $66.4M-$0.18-$0.19 – -$0.171
FY29$77.2M$73.7M – $80.0M$0.02$0.02 – $0.021
FY30$95.1M$90.8M – $98.5M$0.26$0.24 – $0.271

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.74%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+14.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+51.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 35.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.505-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 11Harry KovelmanChief Medical Officer15.5K sh$20KSellSep 2Morris Milton MayoDirector15.0K sh$21KSellAug 20Harry KovelmanChief Medical Officer17.5K sh$30KSellAug 20Harry KovelmanChief Medical Officer17.3K sh$30KBuyJun 5Thomas F KirkDirector40.0K sh$51KBuyMay 28Thomas F KirkDirector25.0K sh$25KSellMay 28Harry KovelmanChief Medical Officer11.5K sh$12KSellMay 27Harry KovelmanChief Medical Officer20.5K sh$21KBuyMay 18Thomas F KirkDirector43.4K sh$39KBuyMay 15Joseph M. MankoDirector30.4K sh$27K
1–10 of 13
+ 26 other (15 awards · 11 inkinds) in window

See when $MYO insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-K/AOfficer or director change (amended)Jun 298-K/A — Item 5.02: Officer or director change · Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

Myomo, Inc. (MYO) filed Amendment No. 1 to its June 26, 2026 Form 8-K solely to correct exhibit labeling errors. Amendment No. 3 to the 2018 Stock Option and Incentive Plan, previously mislabeled as Exhibit 3.1, is now properly labeled as Exhibit 10.1, and the amendment to the Company's Eighth Amended and Restated Certificate of Incorporation, previously mislabeled as Exhibit 10.1, is now properly labeled as Exhibit 3.1. Appropriate hyperlinks in Item 9.01 were also added. No substantive changes were made to any disclosed matters from the June 25, 2026 Annual Meeting, which covered the equity plan share increase, charter amendment, and director elections.

8-KOfficer or director changeJun 268-K — Item 5.02: Officer or director change · Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

Myomo, Inc. (MYO) reported results from its June 25, 2026 Annual Meeting of Stockholders, at which shareholders approved three significant measures. Stockholders approved an amendment to the 2018 Stock Option and Incentive Plan increasing available shares by 1,833,000, and approved a charter amendment increasing authorized common stock to 100,000,000 shares, with the charter amendment becoming effective upon same-day filing with the Delaware Secretary of State. The annual meeting also included director elections and other routine proposals. Myomo develops powered orthoses — motorized braces — for people with upper-limb paralysis resulting from stroke or incomplete spinal cord injury.

SC 13D/AActivist amendmentMay 18SC 13D/A
3New insider — initial holdingsMay 183
8-KOfficer or director changeMay 138-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
3New insider — initial holdingsApr 163
8-KOfficer or director changeApr 168-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
+ 12 other (2 10-Qs · 2 earnings 8-Ks · 2 proxys · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conferencebusinesswire.com·28d agoMyomo Q2 Earnings Call Highlightsmarketbeat.com·51d agoMyomo, Inc. (MYO) Q2 2026 Earnings Call Transcriptseekingalpha.com·55d agoMyomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimateszacks.com·55d agoMyomo Reports Second Quarter 2026 Financial and Operating Resultsbusinesswire.com·55d ago

In themes

Explore the broader themes this ticker is being talked about under.

Robotics & Humanoids

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TMDX$BFLY$BIO$ABT$MDT$BSX$GEHC$SYK
Voices on X · last 7 days

No standout posts about $MYO on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport